在计划接受手术的转移性结直肠癌患者中，贝伐单抗中断治疗后肿瘤生长加速可逆。 - Suppr

Suppr

超能文献

Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery.

作者信息

Cacheux W, Boisserie T, Staudacher L, Vignaux O, Dousset B, Soubrane O, Terris B, Mateus C, Chaussade S, Goldwasser F

出版信息

Ann Oncol. 2008 Sep;19(9):1659-61. doi: 10.1093/annonc/mdn540. Epub 2008 Aug 5.

DOI:10.1093/annonc/mdn540

PMID:18684697

Abstract

摘要

相似文献

Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery.在计划接受手术的转移性结直肠癌患者中，贝伐单抗中断治疗后肿瘤生长加速可逆。

Ann Oncol. 2008 Sep;19(9):1659-61. doi: 10.1093/annonc/mdn540. Epub 2008 Aug 5.

Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.贝伐珠单抗联合化疗治疗转移性结直肠癌患者的安全性和有效性的回顾性队列研究：HGCSG0801 研究。

Jpn J Clin Oncol. 2011 Apr;41(4):490-7. doi: 10.1093/jjco/hyr008. Epub 2011 Feb 7.

Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.新辅助FOLFOX联合贝伐单抗治疗不可切除转移性结直肠癌的病理完全缓解

Clin Colorectal Cancer. 2008 Mar;7(2):140-3. doi: 10.3816/CCC.2008.n.019.

Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases.术前使用贝伐单抗不会显著增加接受结直肠癌肝转移肝手术患者的术后并发症发生率。

J Clin Oncol. 2008 Nov 10;26(32):5254-60. doi: 10.1200/JCO.2008.17.7857. Epub 2008 Oct 14.

Neoadjuvant therapy with bevacizumab.使用贝伐单抗的新辅助治疗。

J Clin Oncol. 2006 Jun 1;24(16):2592-3; author reply 2593-4. doi: 10.1200/JCO.2005.05.2910.

[A case of pathological complete response of metachronous multiple liver metastases from colorectal cancer after mFOLFOX+bevacizumab chemotherapy].[1例结直肠癌异时性多发肝转移经mFOLFOX+贝伐单抗化疗后达到病理完全缓解的病例]

Gan To Kagaku Ryoho. 2009 Nov;36(12):2166-8.

Safety of 10 min infusion of bevacizumab in combination with 5FU-based chemotherapy in non-selected metastatic colorectal cancer patients.在未选择的转移性结直肠癌患者中，贝伐单抗与基于5-氟尿嘧啶的化疗联合输注10分钟的安全性。

Dig Liver Dis. 2011 Mar;43(3):248-9. doi: 10.1016/j.dld.2010.10.013. Epub 2010 Dec 9.

Aneurysm formation in an angiomyolipoma during bevacizumab combination therapy.贝伐单抗联合治疗期间血管平滑肌脂肪瘤中动脉瘤的形成。

Acta Oncol. 2010 Aug;49(6):864-6. doi: 10.3109/02841861003649257.

Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.在一组非选择性转移性结直肠癌患者中，短期输注贝伐单抗联合基于5-氟尿嘧啶的化疗作为一线治疗方案。

Acta Oncol. 2010 Apr;49(3):395-6. doi: 10.3109/02841860903428184.

Correlation between response to chemotherapy with concomitant bevacizumab for hepatic metastasis of colorectal cancer and degree of enhancement using contrast-enhanced computed tomography.结直肠癌肝转移化疗联合贝伐珠单抗的疗效与增强 CT 增强程度的相关性。

Cancer Chemother Pharmacol. 2013 Jul;72(1):209-15. doi: 10.1007/s00280-013-2186-x. Epub 2013 May 14.

引用本文的文献

Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study.在接受阿替利珠单抗联合贝伐珠单抗治疗的不可切除肝细胞癌患者中，因贝伐珠单抗特殊关注不良事件而跳过贝伐珠单抗的影响：III期IMbrave150研究的探索性分析

Liver Cancer. 2023 Nov 28;13(4):401-412. doi: 10.1159/000535501. eCollection 2024 Aug.

A cancer cell membrane coated, doxorubicin and microRNA co-encapsulated nanoplatform for colorectal cancer theranostics.一种用于结直肠癌诊疗的癌细胞膜包覆、共包载阿霉素和微小RNA的纳米平台。

Mol Ther Oncolytics. 2022 Dec 7;28:182-196. doi: 10.1016/j.omto.2022.12.002. eCollection 2023 Mar 16.

Glycocalyx Acts as a Central Player in the Development of Tumor Microenvironment by Extracellular Vesicles for Angiogenesis and Metastasis.糖萼通过细胞外囊泡在肿瘤微环境的发展中作为血管生成和转移的核心参与者。

Cancers (Basel). 2022 Nov 3;14(21):5415. doi: 10.3390/cancers14215415.

Novel Pathways for Targeting Tumor Angiogenesis in Metastatic Breast Cancer.转移性乳腺癌中靶向肿瘤血管生成的新途径

Front Oncol. 2021 Dec 3;11:772305. doi: 10.3389/fonc.2021.772305. eCollection 2021.

Pneumatosis intestinalis associated with lenvatinib during thyroid cancer treatment: a case report.治疗甲状腺癌期间仑伐替尼相关的肠气肿：一例报告。

J Med Case Rep. 2021 Nov 12;15(1):556. doi: 10.1186/s13256-021-03158-w.

Resistance Mechanisms of Anti-angiogenic Therapy and Exosomes-Mediated Revascularization in Cancer.癌症中抗血管生成治疗及外泌体介导的血管再生的耐药机制

Front Cell Dev Biol. 2020 Dec 9;8:610661. doi: 10.3389/fcell.2020.610661. eCollection 2020.

A Novel Antitumor Strategy: Simultaneously Inhibiting Angiogenesis and Complement by Targeting VEGFA/PIGF and C3b/C4b.一种新型抗肿瘤策略：通过靶向VEGFA/PIGF和C3b/C4b同时抑制血管生成和补体

Mol Ther Oncolytics. 2019 Dec 14;16:20-29. doi: 10.1016/j.omto.2019.12.004. eCollection 2020 Mar 27.

Revascularization after angiogenesis inhibition favors new sprouting over abandoned vessel reuse.血管生成抑制后的再血管化有利于新的发芽而不是废弃血管的再利用。

Angiogenesis. 2019 Nov;22(4):553-567. doi: 10.1007/s10456-019-09679-9. Epub 2019 Sep 4.

Discontinuous Schedule of Bevacizumab in Colorectal Cancer Induces Accelerated Tumor Growth and Phenotypic Changes.贝伐单抗间断给药方案在结直肠癌中可诱导肿瘤加速生长及表型改变。

Transl Oncol. 2018 Apr;11(2):406-415. doi: 10.1016/j.tranon.2018.01.017. Epub 2018 Feb 20.

Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers.贝伐珠单抗联合吉西他滨和顺铂治疗晚期胆道癌可提高生存率。

Invest New Drugs. 2018 Feb;36(1):156-162. doi: 10.1007/s10637-017-0492-6. Epub 2017 Aug 1.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验